What is he best known for?
The fields of study he is best known for:
The scientist’s investigation covers issues in Cancer research, Multiple myeloma, Bortezomib, Bone marrow and Proteasome inhibitor.
His Cancer research research includes themes of Cell culture, Cell growth, Apoptosis, Histone deacetylase and Signal transduction.
His research in Multiple myeloma intersects with topics in Pharmacology and Dexamethasone.
His Bortezomib study combines topics from a wide range of disciplines, such as Tumor microenvironment and IκB kinase.
His studies in Bone marrow integrate themes in fields like Natural killer cell, Stromal cell, Cell killing and Peripheral blood mononuclear cell.
Teru Hideshima combines subjects such as Cancer cell, Ubiquitin, IκBα and Cytokine secretion with his study of Proteasome inhibitor.
His most cited work include:
- A phase 2 study of bortezomib in relapsed, refractory myeloma. (2325 citations)
- The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. (1394 citations)
- NF-κB as a Therapeutic Target in Multiple Myeloma * (856 citations)
What are the main themes of his work throughout his whole career to date?
Teru Hideshima spends much of his time researching Cancer research, Multiple myeloma, Bortezomib, Bone marrow and Stromal cell.
His biological study spans a wide range of topics, including Cell culture, Apoptosis, Protein kinase B, Cell growth and Immunology.
The study incorporates disciplines such as Transplantation and Dexamethasone in addition to Multiple myeloma.
His research integrates issues of Proteasome inhibitor, Proteasome, Kinase and Pharmacology in his study of Bortezomib.
His work carried out in the field of Bone marrow brings together such families of science as Osteoclast, Angiogenesis and Peripheral blood mononuclear cell.
His studies deal with areas such as Cytotoxic T cell, Cytokine secretion, Cytokine and Cell adhesion as well as Stromal cell.
He most often published in these fields:
- Cancer research (59.35%)
- Multiple myeloma (39.26%)
- Bortezomib (38.49%)
What were the highlights of his more recent work (between 2012-2021)?
- Cancer research (59.35%)
- Multiple myeloma (39.26%)
- Bortezomib (38.49%)
In recent papers he was focusing on the following fields of study:
Teru Hideshima focuses on Cancer research, Multiple myeloma, Bortezomib, Bone marrow and Cell growth.
His Cancer research study combines topics in areas such as Immune system, Immunology, Cell culture and Cytotoxic T cell.
His Multiple myeloma research is multidisciplinary, incorporating elements of Cancer, Oncology and Proteasome.
His Bortezomib research integrates issues from Proteasome inhibitor, Apoptosis and Immunogenic cell death.
His study in Proteasome inhibitor is interdisciplinary in nature, drawing from both Histone deacetylase and Cytotoxicity.
His study in Bone marrow is interdisciplinary in nature, drawing from both Mesenchymal stem cell, Side population and CD38.
Between 2012 and 2021, his most popular works were:
- Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans (227 citations)
- Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma (181 citations)
- Rescue of Hippo coactivator YAP1 triggers DNA damage-induced apoptosis in hematological cancers (153 citations)
In his most recent research, the most cited papers focused on:
His scientific interests lie mostly in Cancer research, Multiple myeloma, Cell growth, Bortezomib and Immunology.
Teru Hideshima has researched Cancer research in several fields, including Apoptosis, Gene knockdown, Downregulation and upregulation, Histone deacetylase and Molecular biology.
His research in Apoptosis intersects with topics in Cell culture, Cell, DNA damage and Cytotoxicity.
The various areas that Teru Hideshima examines in his Multiple myeloma study include Stromal cell, PI3K/AKT/mTOR pathway, Bone marrow and In vivo.
In his study, which falls under the umbrella issue of Cell growth, DNMT1, STAT3, HDAC3 and Carcinogenesis is strongly linked to Histone deacetylase 2.
His Bortezomib research integrates issues from NAD+ kinase, Nicotinamide phosphoribosyltransferase and Proteasome.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
